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Preclinical data suggest that the anti-tumour activity of capecitabine is enhanced by taxanes and mitomycin C through up-regulation of
thymidine phosphorylase (TP). Here, we studied safety and efficacy of the combination of capecitabine with docetaxel and mitomycin
C. Two dose levels (DL) were investigated: capecitabine 1000mgm
 2 b.i.d. on days 1–14, docetaxel 40mgm
 2 i.v. day 1, mitomycin
C4o r6m gm
 2 i.v. day 1 (DL I or II). Cycles were repeated every 3 weeks. The primary aim was to determine the dose-limiting
toxicities (DLT) during the first two treatment cycles and the maximum tolerated dose (MTD). A total of 46 patients (pts) refractory
to standard therapies were enrolled, of whom the majority had gastrointestinal tumours (n¼40). 14 pts had received X3 lines of
prior chemotherapy. At DL I, one out of six pts experienced DLT. At DL II, two out of six pts had DLT (mucositis grade 3). Thus, DL I
was determined as MTD. Among a total of 37 pts treated on DL I the following toxicities were observed during cycles 1 and 2
(number of patients with grade 1/2/3/4 toxicity; NCI-CTC v. 3.0): anaemia 10/8/3/0, leucocytopenia 4/11/1/2, thrombocytopenia 0/1/
2/0, diarrhoea 8/1/2/0, stomatitis/mucositis 3/3/1/0, nausea/vomiting 10/2/0/0, and hand-foot skin reaction 5/1/1/0. Of 30 pts who
received at least two treatment cycles nine achieved complete or partial remissions, six pts achieved minor remissions, and seven pts
had stable disease (tumour control rate 73%). Of note, four out of 10 patients with pancreatic cancer had partial remissions. In
conclusion, capecitabine can safely be combined with docetaxel (40mgm
 2) and mitomycin C (4mgm
 2). The established regimen
was well tolerated and the preliminary efficacy data in this heavily pre-treated patients population appears to be promising.
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To date, no standard recommendations for salvage therapies exist
for most types of gastrointestinal tumours with the exception of
colorectal cancer. A benefit of salvage therapy has clearly been
demonstrated in this disease in three clinical trials comparing
either irinotecan, panitumumab or cetuximab against best
supportive care (Cunningham et al, 1998; Au et al, 2007; van
Cutsem et al, 2007). Randomized trials addressing the question of
salvage treatment in other gastrointestinal cancers have not been
published so far, and the question how to treat patients with
gastrointestinal cancer once beyond the control of first line
therapy is unanswered.
Capecitabine, an orally administered fluoropyrimidine carba-
mate produces high concentrations of 5-fluorouracil (5-FU)
preferentially in tumour tissue. It is converted to its active
metabolite 5-FU through a three-step enzymatic process, the final
step of which is mediated by the enzyme thymidine phosphorylase
(TP) (Schuller et al, 2000). Among various cytostatics studied in
combination with capecitabine in human cancer xenografts, the
taxanes and mitomycin C had the highest potential of increasing
the activity of intratumoural TP (Sawada et al, 1998). Thus, in an
attempt to increase the cytotoxic potential of capecitabine, several
studies were conducted using capecitabine in combination with
one of these TP inductors.
In a previous trial we established a combination regimen of
capecitabine and mitomycin C which showed a favourable safety
profile and promising activity in patients with pre-treated
gastrointestinal cancer (Hofheinz et al, 2004). Phase-II studies
have confirmed the encouraging activity of this combination with
an acceptable toxicity profile in patients with pre-treated (Chong
et al, 2005) or chemotherapy-naı ¨ve (Rao et al, 2004) advanced
colorectal cancer. In a randomised phase-II trial comparing
mitomycin C with either capecitabine or gemcitabine in patients
with advanced biliary tract cancer, the mitomycin C plus
capecitabine combination was superior in terms of response rate,
progression-free survival and overall survival (Kornek et al, 2004).
Capecitabine plus mitomycin C has been demonstrated to be an
effective and well tolerated treatment option even in advanced
breast cancer patients resistant to anthracyclines and taxanes
(Maisano et al, 2005; Massacesi et al, 2006).
The clinical impact of up-regulating TP has further been
demonstrated for capecitabine in combination with docetaxel in
a variety of human malignancies in phase-I studies (Pronk et al,
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s2000; Nadella et al, 2002). In a large phase-III trial the addition of
capecitabine to docetaxel resulted in a significant superior survival
over single-agent docetaxel in 511 anthracycline-pretreated
patients with advanced breast cancer (O’Shaughnessy et al,
2002). This randomised trial revealed that the combination of
both drugs provided clear benefits over single-agent docetaxel in
terms of objective tumour response rate (42 vs 30%), time to
progression (median, 6.1 vs 4.2 months), and overall survival
(median, 14.5 vs 11.5 months). Furthermore, several phase-II
studies on the combination of capecitabine and docetaxel showed
activity in patients with metastatic gastric cancer (Chun et al, 2005;
Giordano et al, 2006), metastatic oesophageal cancer (Lorenzen
et al, 2005), advanced non-small cell lung cancer (Han et al, 2003;
Kindwall-Keller et al, 2005), and prostate cancer (Morant et al,
2004; Ferrero et al, 2006).
With the present trial, we sought to establish a three-drug
regimen combining capecitabine with both of the preclinical most
potent TP inductors, docetaxel and mitomycin C. The primary aim
of this clinical trial was to determine the dose-limiting toxicities
and the recommended dose of 3-weekly docetaxel and mitomycin
C in combination with standard capecitabine in patients with pre-
treated tumours.
PATIENTS AND METHODS
The study protocol was reviewed and approved by the local
institutional review board and the study was performed according
to the Declaration of Helsinki. All patients provided written
informed consent prior to entry into the study.
Eligibility criteria
Patients with histological confirmed locally advanced or metastatic
cancer refractory to or relapsed after at least one palliative
chemotherapy regimen were eligible for entry into the study.
Additional inclusion criteria comprised: Eastern Cooperative
Oncology Group (ECOG) performance status p2, age X18 years,
life expectancy X3 months, measurable disease, left ventricular
ejection fraction (LVEF) 450%, cardiac insufficiency NYHA o2,
adequate bone marrow function (leucocyte count X3000ml
 1,
platelet count X100000ml
 1), and adequate renal (serum creati-
nine p1.4mgdl
 1 or creatinine clearance 460mlmin
 1) and
hepatic function (bilirubin p2mgdl
 1).
Staging procedures
Before study admission, all patients underwent a complete history,
physical examination, ECG and chest X-rays. Cardiac ultrasono-
graphy was carried out to determine the LVEF. A full blood count
with differential and serum chemistry was obtained within 14 days
prior to the start of treatment. Weekly blood counts were obtained
and serum chemistry repeated every third week or whenever
clinically indicated. Assessment of LVEF was repeated before the
initiation of every other treatment cycle. Computed tomography
(CT) scans of the tumour-bearing region were performed within
four weeks prior to the start of study treatment. Indicator lesions
were assessed every six weeks.
Treatment schedule and dose escalation
Capecitabine was administered orally within 30min after a meal
(generally after breakfast and evening meal) at a dose of
1000mgm
 2 b.i.d. on days 1 14 for all dose levels (DL). At DL I
and II docetaxel was administered at a dose of 40mgm
 2 and
mitomycin C was given as an i.v. bolus of 4mgm
 2 (DL I) or
6mgm
 2 (DL II) on day 1, respectively. At DL III and IV
mitomycin C was scheduled at a fixed dose of 6mgm
 2, and
docetaxel was administered at a dose of 50mgm
 2 (DL III) or
60mgm
 2 (DL IV) on day 1. Cycles were repeated every three
weeks. Dexamethasone 8mg was added intravenously prior to
docetaxel/mitomycin C infusion, and all patients received standard
antiemetic prophylaxis with 5-HT3 antagonists to avoid any bias
relating to gastrointestinal toxicities. A maximum cumulative dose
of mitomycin C was not defined in the study protocol. Never-
theless, a thorough monitoring for parameters of haemolysis/
haemolytic-uraemic syndrome was foreseen by the study protocol.
Dose-limiting toxicities (DLT) during the first two cycles of
chemotherapy were defined by the occurrence of one of the
following toxicities: grade 4 leucocytopenia/neutropenia or throm-
bocytopenia, symptomatic thrombocytopenia (haemorrhage),
grade 3 or 4 febrile neutropenia or anyXgrade 3 non-haemato-
logical toxicity except nausea/vomiting. At least three patients were
enrolled per dose level, with this number being increased to six if
DLT occurred in one patient. Dose escalation was halted if DLT
occurred in two or more patients. The maximum tolerated dose
(MTD) was defined as the highest dose at which not more than one
out of six patients experienced DLT during the first and second
course of chemotherapy (i.e. days 1–42). Individual dose
escalation was not allowed. In order to adequately determine the
safety of this combination, the recruitment of further patients at
the MTD was foreseen by the study protocol.
Safety and efficacy analyses
Adverse events were recorded weekly and graded according to the
National Cancer Institute Common Toxicity Criteria (NCI-CTC,
version 3.0). In terms of efficacy, complete response (CR), partial
response (PR), minor response (MR), stable disease (SD) and
progressive disease (PD) were defined according to WHO criteria.
Survival was defined as the time between the start of chemotherapy
and death, according to the Kaplan Meier method (Kaplan and
Maier, 1958). Progression-free survival was defined as the time
between the start of chemotherapy and clinical signs of progressive
disease.
Statistical considerations
For confirmation of the safety of this new regimen the recruitment
of further patients at the recommended dose level was foreseen.
The frequency of patients experiencing DLT during this expanded
study phase was required to be lower than 17% (i.e. about one out
of six of the patients experiencing DLT). With a total of 32
patients, a rate of at least 83% of the patients experiencing no DLT
during cycles one and two can be excluded using Simon’s two-
stage design with a power of 80% and an a-value of 20% if less than
five out of 15 (first stage) or peight out of 32 patients (second
stage) experienced DLT.
RESULTS
Patients’ characteristics
A total of 46 patients were enrolled at our institution between July
2004 and January 2007. All patients were evaluable for safety.
Characteristics of enrolled patients are described in Table 1. The
majority of patients (72%) had an ECOG status p1. Pancreatic
cancer (28%), biliary tract cancer (22%), colorectal and oesopha-
geal cancer (15%, each) were the most common malignancies. The
liver (74%) and lymph nodes (41%) were the most common sites
of metastases, followed by the lung (30%) and bone (17%). All
patients with oesophageal and biliary tract cancers had measurable
disease.
Patients had received a median of one line (range 1–6) of prior
palliative chemotherapy (14 patients with X3 lines) and 25
patients (54%) had received prior 5-FU-based treatment.
Combination therapy in pre-treated tumour patients
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sDetermination of the MTD and dose intensity
One of the first six patients at DL I had DLT (diarrhoea grade 3)
and consequently DL II was opened. At DL II nine patients were
included. Of these, two patients were not evaluable due to rapid
clinical deterioration. Another patient had a non-toxicity-related
treatment break of 2,5 weeks between the first and second
treatment cycle and was not amenable for the determination of
DLT. Two out of the first six evaluable patients included at DL II
had DLT (mucositis grade 3) and three patients had leucocyto-
penia grade 3. Thus, DL I was determined as MTD, and as the
recommended dose level for the recruitment of further patients.
Thirty-seven patients were enrolled at dose level I. These
patients received a total of 157 cycles (median 4, range 1–13) of
chemotherapy. In all, only five patients treated at this DL had DLT
during the first four cycles: leucocytopenia grade 4 with mucositis
grade 3, leucocytopenia grade 4, mucositis grade 3, hand-foot
syndrome grade 3 with diarrhoea grade 3, diarrhoea grade 3, n¼1
each. Eight patients stopped treatment after cycle one for the
following reasons: DLT (leucocytopenia grade 4, n¼1; hand-foot
syndrome grade 3 with diarrhoea grade 3, n¼1), worsening of
general condition (n¼3), death due to tumour progression
(n¼2), consent withdrawn (n¼1). At dose level I, 29 out of 37
patients received a minimum of two complete cycles. Of these, 20
patients received at least four cycles, and 15 had five or more
cycles of therapy.
Nine patients were enrolled at dose level II. These patients received
a total of 32 cycles (median¼2, range 1–14) of chemotherapy. Four
patients stopped treatment after one cycle for the following reasons:
DLT (mucositis grade 3, n¼2), death due to tumour progression
(n¼1), worsening of general condition (n¼1). Five patients received
a minimum of two complete cycles, three of whom received at least
four cycles and two patients five or more cycles of therapy.
Dose intensity was calculated for patients treated at the
recommended DL I who received at least two complete cycles of
chemotherapy (29/37 patients). A median dose intensity of 100%
was reached during cycles one and two for each drug. The relative
mean values with respect to cycles one and two were as follows:
capecitabine 96%, mitomycin and docetaxel 100%, respectively.
With respect to cycles three and four, the values were as follows
(median/mean; n¼20 patients): capecitabine 100/96, docetaxel
100/98, mitomycin C 100/99.
Postponement of treatment during cycles one and two was
required in three patients only with a mean delay of 20 days
(range, 14–24 days). Two of the 20 patients receiving a third or
fourth cycle of therapy had a treatment delay with a mean delay of
11 days (range, 7–14 days).
At the recommended dose level I, the mean cumulative dose of
mitomycin C was 31mg (median 28mg; range 6–91mg). 13 of 37
patients (35%) received more than 36mg of mitomycin C and two
patients received more than 76mg.
Safety
Table 2 summarises haematological and non-haematological
adverse events during cycles one and two (the time period for
the determination of DLT, i.e. days 1–42) and cycles three and
four. At DL I, a total of 37 patients were evaluable for safety.
Anaemia (n¼21), leucocytopenia (n¼18), fatigue (n¼16),
nausea/vomiting (n¼12) and diarrhoea (n¼11) were the most
commonly observed adverse events during cycles one and two.
Leucocytopenia grade 4 was observed in two patients (5%). Grade
3 toxicities were recorded in nine patients (24%): anaemia (n¼3),
thrombocytopenia (n¼2), diarrhoea (n¼2), leucocytopenia,
mucositis, hand-foot skin reaction, fatigue (n¼1, each).
During cycles three and four (n¼23 patients), anaemia (n¼15),
hand-foot syndrome (n¼10) and leucocytopenia (n¼9) were the
most commonly observed adverse events.
No evidence of mitomycin C-induced haemolytic-uraemic
syndrome or pulmonary toxicity was documented.
Anti-tumour activity
30 patients received at least two cycles of treatment and were
evaluable for response analysis. One patient with oesophageal and
one with biliary tract cancer achieved a complete remission,
respectively. Seven patients achieved partial remissions (pancreatic
cancer n¼4, biliary tract cancer n¼1, oesophageal cancer n¼1,
head and neck tumour n¼1), six patients achieved minor responses
(pancreatic cancer n¼4, biliary tract cancer n¼1, oesophageal
cancer n¼1), and seven patients had stable disease. Anti-tumour
activity is summarized in Table 3. Thus, in total 15/30 (50%) achieved
any kind of response and 7/30 (23%) had stable disease adding to a
tumour control rate of 73%. Only 8/30 (27%) had progressive disease
after cycle 2 while receiving therapy. Remarkably, all of four patients
with colorectal cancer had a progressive disease.
The median progression-free survival for all patients (n¼46)
was 3.2 months (range, 0.2–15.8þ), for patients with any kind
of tumour response or stable disease (n¼22) 5.0 months
(1.7–15.8þ). The duration of the complete remissions observed
were 15.8þ months (biliary tract cancer) and 5 months
(oesophageal cancer). The median survival for all patients was
Table 1 Patient demographics
Variable No. of patients (%)
Enrolled 46
Dose Level 1 37 (80)
Dose Level 2 9 (20)
Age (years)
Median 63
Range 43–78
Gender
Male 29 (63)
Female 17 (37)
Performance status (ECOG)
Median 1
0 8 (18)
1 25 (54)
2 13 (28)
Primary tumour site
Pancreatic cancer 13 (28)
Biliary tract cancer 10 (22)
Colorectal cancer 7 (15)
Oesophageal cancer 7 (15)
Cancer of unknown primary 3 (7)
Head and neck tumour 3 (7)
Gastric cancer 1 (2)
Hepatocellular carcinoma 1 (2)
Small intestinal cancer 1 (2)
Prior chemotherapy
1 Line 25 (54)
2 Lines 7 (15)
X3 Lines 14 (31)
5-FU based (i.v. or oral) 25 (54)
Tumour localisation
Primary 19 (41)
Liver 34 (74)
Lung 14 (30)
Lymph nodes 19 (41)
Bone 8 (17)
Peritoneal carcinomatosis 5 (11)
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s5.2 months (0.5–17.1þ), for patients with tumour response or
stable disease 8.2 months (2.1–17.1þ), for patients with
progressive disease 4.5 months (2.4–7.2þ).
DISCUSSION
Docetaxel as well as mitomycin C caused an up-regulation of
thymidine phosphorylase (TP) activity and an enhancement of
capecitabine efficacy in a human xenograft model (Sawada et al,
1998). TP activity is frequently induced in human cancers and its
induction protects cells from apoptosis and stimulates angio-
genesis (Toi et al, 2005). Since TP-targeting treatment has been
developed in parallel with analyses of biological functions and
translational research, therapies targeting this enzyme might be a
rationale chemotherapeutic approach. Combinations between
TP-inducible treatments and TP-targeting therapies seem to have
improved response and survival in patients with various types of
cancer, e.g. breast cancer (O’Shaughnessy et al, 2002). In the
present extended phase-I trial we sought to combine capecitabine,
a TP-targeting therapy with the two most potent TP-inducing
chemotherapeutics, docetaxel and mitomycin C.
Our current findings indicate that capecitabine 1000mgm
 2
orally b.i.d. on days 1–14 in combination with docetaxel
40mgm
 2 and mitomycin C 4mgm
 2 i.v. day 1 every 3 weeks is
both effective and well tolerated. Moreover, this regimen appears
to be convenient using i.v. application in 3-weekly intervals. Dose
escalation in this phase I study continued only to DL II. Due to two
patients suffering DLT (mucositis grade 3) at this dose level, DL I
was determined as MTD. Haematological adverse events, pre-
dominantly anaemia and leucocytopenia were the most commonly
observed adverse events in a total of 37 patients treated at the
MTD. Twenty patients received at least four cycles of chemotherapy
on DL I and the toxicity profile observed during the following
cycles was comparable. Only hand-foot skin reaction was more
frequent in cycles three and four. The median dose intensity was
maintained at 100% during the first four cycles for each drug. In
addition, there were no episodes of haemolytic uraemic syndrome
or pulmonary toxicities during the study.
The preliminary activity (response rate 30%, tumour control
rate 73%) observed in 30 patients evaluable for efficacy appeared
to be promising in view of the high number of patients with
previous 5-FU exposure and the high rate of heavily pre-treated
patients in this study. Of note, these results were obtained with
comparably low doses of three-weekly docetaxel (40mgm
 2) and
mitomycin C (4mgm
 2). These findings underline our hypothesis
that the clinical activity might even be increased by the
combination of two instead of one TP-inductor(s) with the TP-
targeting agent capecitabine. Of course, these results need
confirmation by phase-II trials in distinct tumour entities.
Three-drug regimens containing capecitabine and mitomycin C
have not been reported, while several three-drug combinations
containing capecitabine and docetaxel have been published.
Capecitabine, docetaxel and gemcitabine were investigated in a
phase-I trial in various solid tumours by Amarantidis and
coworkers (Amarantidis et al, 2006). The toxicity in 18 patients
was described to be generally mild, and responses were seen in
some patients. Thirty-five patients with metastatic pancreatic
cancer (66% of them chemotherapy-naı ¨ve) received this three-drug
regimen in a recently published study (Fine et al, 2008). A
comparably high rate of tumour remissions (29%) was reported,
but the rate of grade 3–4 thrombocytopenia (14%) was higher than
in the present trial (5%). Other investigators added cisplatin in a
variety of solid tumours (Fakih et al, 2005), carboplatin in
metastatic oesophagogastric cancer (Tsai et al, 2005) or epirubicin
in patients with advanced breast cancer (Venturini et al, 2003) to
the combination of capecitabine and docetaxel. Particularly the
phase-II study of Venturini et al described promising anti-tumour
activity in a total of 67 patients with chemotherapy-naı ¨ve
metastastic breast cancer (response rate 82%). Nevertheless, a
total of 16% of the patients had febrile neutropenia.
In conclusion, we have established a three-drug dosing schedule
for the combination of capecitabine, docetaxel, and mitomycin C
that is well tolerated and showed encouraging signs of activity
especially in patients with pancreatic, biliary tract and oesophageal
cancer. This regimen may be considered for patients after failure of
pre-treatment but it is also likely to be a valuable, cost-saving and
convenient treatment option even in earlier stages of cancer
chemotherapy.
Table 2 Haematological and non-haematological adverse events per dose level in cycles 1/2 and 3/4 (worst per patient)
No. of patients/NCI-CTC grade
a
Dose level 1 (n¼37) Dose level 2 (n¼9)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Cycles 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4
Anaemia 1 09 8 6 3 ———4 1 3 2————
Leucocytopenia 4 — 1 17122 — 111 — 32— —
Thrombocytopenia — 2 1— 2 ————— 1 —————
Nausea/vomiting 1 04 2—————3—1—————
Stomatitis/mucositis 3 3 3 2 1 1 —————— 2 ———
Diarrhoea 8 2 1 3 2 ———— 1 ——————
Hand-foot skin reactions 5 7 1 3 1 ———————————
Alopecia 55 32——— — — —2 1— ———
Fatigue 1 1 3 4 4 1 ——— 3 ———————
Polyneuropathy 73——————————————
Renal function (creatinine) 2 2 2 1 ————————————
aGraded according to the National Cancer Institute Common Toxicity Criteria (version 3.0).
Table 3 Anti-tumour activity in patients who received a minimum of
two cycles of chemotherapy
Tumour type n CR PR MR SD PD
Pancreatic cancer 10 0 4 4 2 0
Biliary tract cancer 7 1 1 1 2 2
Oesophageal cancer 6 1 1 1 2 1
Colorectal cancer 4 0 0 0 0 4
Others 3 0 1 0 1 1
CR¼complete remission; PR¼partial remission; MR¼minor remission; SD¼stable
disease; PD¼progressive disease.
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